|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giaccone G, Gallegos Ruiz M, Le Chevalier
T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D and
Soria JC: Erlotinib for frontline treatment of advanced non-small
cell lung cancer: A phase II study. Clin Cancer Res. 12:6049–6055.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakazawa Y, Saha S, Galvan DL, Huye L,
Rollins L, Rooney CM and Wilson MH: Evaluation of long-term
transgene expression in piggyBac-modified human T lymphocytes. J
Immunother. 36:3–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Riely GJ, Kris MG, Zhao B, Akhurst T,
Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH and
Miller VA: Prospective assessment of discontinuation and
reinitiation of erlotinib or gefitinib in patients with acquired
resistance to erlotinib or gefitinib followed by the addition of
everolimus. Clin Cancer Res. 13:5150–5155. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko
TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, et al: A
common BIM deletion polymorphism mediates intrinsic resistance and
inferior responses to tyrosine kinase inhibitors in cancer. Nat
Med. 18:521–528. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao M, Zhang Y, Cai W, Li J, Zhou F,
Cheng N, Ren R, Zhao C, Li X, Ren S, et al: The Bim deletion
polymorphism clinical profile and its relation with tyrosine kinase
inhibitor resistance in Chinese patients with non-small cell lung
cancer. Cancer. 120:2299–2307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O'Connor L, Strasser A, O'Reilly LA,
Hausmann G, Adams JM, Cory S and Huang DC: Bim: A novel member of
the Bcl-2 family that promotes apoptosis. EMBO J. 17:384–395. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
San José-Eneriz E, Agirre X,
Jiménez-Velasco A, Cordeu L, Martín V, Arqueros V, Gárate L,
Fresquet V, Cervantes F, Martínez-Climent JA, et al: Epigenetic
down-regulation of BIM expression is associated with reduced
optimal responses to imatinib treatment in chronic myeloid
leukaemia. Eur J Cancer. 45:1877–1889. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Richter-Larrea JA, Robles EF, Fresquet V,
Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA,
Hernandez JM, et al: Reversion of epigenetically mediated BIM
silencing overcomes chemoresistance in Burkitt lymphoma. Blood.
116:2531–2542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Piazza R, Magistroni V, Mogavero A,
Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB,
Collini P, et al: Epigenetic silencing of the proapoptotic gene BIM
in anaplastic large cell lymphoma through an MeCP2/SIN3a
deacetylating complex. Neoplasia. 15:511–522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zantl N, Weirich G, Zall H, Seiffert BM,
Fischer SF, Kirschnek S, Hartmann C, Fritsch RM, Gillissen B,
Daniel PT and Häcker G: Frequent loss of expression of the
pro-apoptotic protein Bim in renal cell carcinoma: Evidence for
contribution to apoptosis resistance. Oncogene. 26:7038–7048. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singal R and Ginder GD: DNA methylation.
Blood. 93:4059–4070. 1999.PubMed/NCBI
|
|
17
|
Fuks F, Burgers WA, Brehm A, Hughes-Davies
L and Kouzarides T: DNA methyltransferase Dnmt1 associates with
histone deacetylase activity. Nat Genet. 24:88–91. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ju L, Zhou C, Li W and Yan L: Integrin
beta1 over-expression associates with resistance to tyrosine kinase
inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem.
111:1565–1574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li B, Ren S, Li X, Wang Y, Garfield D,
Zhou S, Chen X, Su C, Chen M, Kuang P, et al: MiR-21 overexpression
is associated with acquired resistance of EGFR-TKI in non-small
cell lung cancer. Lung Cancer. 83:146–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toyooka S, Toyooka KO, Maruyama R, Virmani
AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio
K, et al: DNA methylation profiles of lung tumors. Mol Cancer Ther.
1:61–67. 2001.PubMed/NCBI
|
|
22
|
Zöchbauer-Müller S, Fong KM, Virmani AK,
Geradts J, Gazdar AF and Minna JD: Aberrant promoter methylation of
multiple genes in non-small cell lung cancers. Cancer Res.
61:249–255. 2001.PubMed/NCBI
|
|
23
|
Wilting RH and Dannenberg JH: Epigenetic
mechanisms in tumorigenesis, tumor cell heterogeneity and drug
resistance. Drug Resist Updat. 15:21–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Y, Takeuchi S, Hofmann WK, Ikezoe T,
van Dongen JJ, Szczepański T, Bartram CR, Yoshino N, Taguchi H and
Koeffler HP: Aberrant methylation in promoter-associated CpG
islands of multiple genes in acute lymphoblastic leukemia. Leuk
Res. 30:98–102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fujiwara K, Fujimoto N, Tabata M, Nishii
K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H and
Tanimoto M: Identification of epigenetic aberrant promoter
methylation in serum DNA is useful for early detection of lung
cancer. Clin Cancer Res. 11:1219–1257. 2005.PubMed/NCBI
|
|
26
|
Nakagawa T, Takeuchi S, Yamada T, Ebi H,
Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y and Yano
S: EGFR-TKI resistance due to BIM polymorphism can be circumvented
in combination with HDAC inhibition. Cancer Res. 73:2428–2434.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Witta SE, Jotte RM, Konduri K, Neubauer
MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA Jr and Hirsch FR:
Randomized phase II trial of erlotinib with and without entinostat
in patients with advanced non-small-cell lung cancer who progressed
on prior chemotherapy. J Clin Oncol. 30:2248–2255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Capobianco E, Mora A, La Sala D, Roberti
A, Zaki N, Badidi E, Taranta M and Cinti C: Separate and combined
effects of DNMT and HDAC inhibitors in treating human multi-drug
resistant osteosarcoma HosDXR150 cell line. PLoS One. 9:e955962014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leon SA, Shapiro B, Sklaroff DM and Yaros
MJ: Free DNA in the serum of cancer patients and the effect of
therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
|
|
30
|
Stroun M, Anker P, Maurice P, Lyautey J,
Lederrey C and Beljanski M: Neoplastic characteristics of the DNA
found in the plasma of cancer patients. Oncology. 46:318–322. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nawroz H, Koch W, Anker P, Stroun M and
Sidransky D: Microsatellite alterations in serum DNA of head and
neck cancer patients. Nat Med. 2:1035–1037. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mulcahy HE, Lyautey J, Lederrey C, qi Chen
X, Anker P, Alstead EM, Ballinger A, Farthing MJ and Stroun M: A
prospective study of K-ras mutations in the plasma of pancreatic
cancer patients. Clin Cancer Res. 4:271–275. 1998.PubMed/NCBI
|
|
33
|
Ibanez de Caceres I, Battagli C, Esteller
M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg
BL and Cairns P: Tumor Cell-Specific BRCA1 and RASSF1A
Hypermethylation in Serum, Plasma, and Peritoneal Fluid from
Ovarian Cancer Patients. Cancer Res. 64:6476–6481. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK,
Lee HC and Wang YC: Characterization of a multiple epigenetic
marker panel for lung cancer detection and risk assessment in
plasma. Cancer. 110:2019–2026. 2007. View Article : Google Scholar : PubMed/NCBI
|
